RET
Gastrointestinal & Hepatic System · Gastrointestinal Motility & Enteric Plexus
Why can RET be linked to both intestinal nerves and endocrine tumors?
RET makes a receptor that sends signals important for the development and function of several tissues. Different disease-causing changes can disrupt development or promote abnormal growth, so the exact variant and testing context are crucial.
- Common Gene Name
- ret proto-oncogene
- NCBI Gene ID
- 5979
- Chromosome
- 10
Clinical Evidence Status
Actionability report availableEstablished disease relationshipTumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (12 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| multiple endocrine neoplasia type 2B | ClinGen gene-disease validity | Definitive | Autosomal dominant | View source 2020-05-14 |
| multiple endocrine neoplasia type 2A | ClinGen gene-disease validity | Definitive | Autosomal dominant | View source 2020-05-14 |
| Multiple endocrine neoplasia | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2013-08 | |
| Nonsyndromic paraganglioma | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2013-08 | |
| Hirschsprung disease | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2013-08 | |
| Lung cancer | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2013-08 | |
| Multiple Endocrine Neoplasia IIA, Familial Medullary Thyroid Cancer | ClinGen clinical actionability | Scored report; not a validity grade | Adult | View source 2021-10-18 |
| Multiple Endocrine Neoplasia Type IIB | ClinGen clinical actionability | Scored report; not a validity grade | Pediatric | View source 2021-09-13 |
| Multiple Endocrine Neoplasia IIA, Familial Medullary Thyroid Cancer | ClinGen clinical actionability | Scored report; not a validity grade | Pediatric | View source 2022-02-09 |
| Cabozantinib | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Pralsetinib | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Selpercatinib | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Gastrointestinal & Hepatic System